Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry

Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry

IntroductionDual antithrombotic therapy (DAT) combining oral anticoagulation (OAC), preferentially Non-vitamin K antagonist OAC (NOAC) and single antiplatelet therapy (SAPT) for a period of 6–12 months is recommended after percutaneous coronary intervention (PCI) in patients with an indication for O...

Full description

Bibliographic Details
Main Authors: Eric Durand, Thibault Verrez, Andre Gillibert, Thomas Levesque, Thomas Barbe, René Koning, Pascal Motreff, Hélène Eltchaninoff, Jean-Philippe Collet, Gregoire Rangé
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
PCI
VKA
NOAC
bleeding
atrial fibrillation
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1320001/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1320001/full

Similar Items